EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab

Kazuyuki Numakura iD, Noriyuki Abe iD

International Journal of Urology · 2026

DOI: 10.1111/iju.70597 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2026. Verfasst von Kazuyuki Numakura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Ipilimumab, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have become a standard treatment for patients with metastatic renal cell carcinoma (mRCC). The combination of nivolumab and ipilimumab has demonstrated durable responses and survival benefits; however, approximately 20%–25% of patients exhibit primary resistance and derive limited clinical benefit. This review provides a comprehensive overview of current evidence regarding the incidence, clinical predictors, and biological mechanisms of primary resistance to nivolumab plus ipilimumab in mRCC. Key contributing factors include an immunosuppressive tumor microenvironment, metabolic reprogramming, interferon signaling abnormalities, and T‐cell exhaustion. Potential strategies to overcome resistance, such as vascular endothelial growth factor receptor–targeted combinations, biomarker‐driven treatment selection, and novel immune checkpoint targets, are also discussed. A deeper understanding of primary resistance will be essential for the development of mechanism‐based therapeutic strategies and for achieving durable clinical benefit in patients with mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsIpilimumabNivolumabImmune Checkpoint InhibitorsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansTumor MicroenvironmentT-Cell Exhaustion

Stichwörter der Autor:innen

immune checkpoint inhibitorsipilimumabnivolumabprimary resistancerenal cell carcinoma

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.

ORCID-Profile: Kazuyuki Numakura, Noriyuki Abe

Zitieren

APA

Numakura, K., & Abe, N. (2026). Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab. International Journal of Urology. https://doi.org/10.1111/iju.70597

Vancouver

Numakura K, Abe N. Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab. International Journal of Urology. 2026. doi:10.1111/iju.70597

BibTeX
@article{Numakura2026,
  author = {Numakura, Kazuyuki and Abe, Noriyuki},
  title = {Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70597}
}
Kostenlos starten →